Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02118285
Other study ID # 2012LS101
Secondary ID MT2013-11
Status Completed
Phase Phase 1
First received March 26, 2014
Last updated December 3, 2017
Start date July 28, 2014
Est. completion date November 12, 2015

Study information

Verified date December 2017
Source Masonic Cancer Center, University of Minnesota
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a single center phase I trial designed to determine the maximum tolerated dose (MTD) of the oral IDO inhibitor INCB024360 when administered as part of a larger regimen of intraperitoneal (IP) delivery of haploidentical donor NK cells and IL-2 after a non-myeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen for the treatment of recurrent ovarian, fallopian tube, and primary peritoneal cancer.


Description:

Haploidentical donor NK cells and the 1st dose of IL-2 are infused intraperitoneally (IP) after a non-myeloablative preparative regimen of cyclophosphamide and fludarabine. IP IL-2 continues three times a week for 5 additional doses. INCB024360, at the assigned dose, begins 2 days before the NK cell infusion (on day -2) and continues twice daily for 90 days.

Follow-up for disease response and survival is for 1 year from the NK cell infusion with the possibility of re-treatment for patients who experience at least a clinical benefit for a minimum of 6 months prior to disease progression.

The MTD of INCB024360 will be determined using the continual reassessment method (CRM). The 1st 2 patients will be enrolled at dose level 1 (50 mg bid) of INCB024360. Each new cohort of 2 patients will be sequentially assigned to most appropriate dose by the study statistician based on the updated toxicity profile. Up to 4 dose levels of INCB024360 will be tested (50, 100, 200, and 300 mg bid) with a dose level -1 (25 mg bid) used in the event that 50 mg bid proves to be too toxic. The MTD will be identified when the total sample size of 20 patients is exhausted.


Recruitment information / eligibility

Status Completed
Enrollment 2
Est. completion date November 12, 2015
Est. primary completion date November 12, 2015
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of recurrent epithelial ovarian cancer, fallopian tube, or primary peritoneal cancer that has failed or progressed after at least 1 prior salvage chemotherapy regimen directed at recurrent/metastatic disease.

- Measurable disease per disease specific RECIST version 1.1- patients with bone as their only site of disease will not be eligible

- If history of brain metastases must be stable for at least 3 months after treatment - A brain CT scan will only be required in subjects with known brain metastases at the time of enrollment or in subjects with clinical signs or symptoms suggestive of brain metastases.

- Available related HLA-haploidentical NK cell donor by at least Class I serologic typing at the A&B locus

- Age 18 years or older

- GOG Performance Status = 2 - refer to appendix III

- Adequate organ function as determined by the following criteria within 14 days of the start of the preparative regimen, unless otherwise noted:

- Bone marrow: platelets = 80,000 x 109/L and hemoglobin = 9 g/dL, unsupported by transfusions; absolute neutrophil count (ANC) = 1000 x 109/L, unsupported by G-CSF or granulocytes

- Renal function: estimated glomerular filtration rate (GFR) of = 50 ml/min (based on the Fairview Laboratories formula at time of screening)

- Liver function: total bilirubin < 1.5 times upper limit of institutional normal; AST, ALT, and alkaline phosphatase < 3 times upper limit of institutional normal

- Cardiac: Left ventricular ejection fraction > 40% (within 28 days of treatment start)

- Pulmonary function: > 50% corrected DLCO and FEV1, if presence of pleural effusion due to metastatic disease > 40% corrected DLCO and FEV1 is acceptable (within 28 days of treatment start)

- Able to be off prednisone or other immunosuppressive medications other than that prescribed per protocol for at least 3 days prior to Day 0

- At least 14 days must lapse between last prior anti-cancer treatment and 1st day of preparative regimen

- Not pregnant or lactating - The agents used in this study may be teratogenic to a fetus and there is no information on the excretion of agents into breast milk. Participants of childbearing potential must have a blood test or urine study within 14 days prior to registration to rule out pregnancy and agree to use adequate birth control during study treatment.

- Able to tolerate intraperitoneal (IP) port placement and IP treatment administration in the opinion of the enrolling investigator

- Voluntary written consent

Exclusion Criteria:

- Active infection - must be afebrile and off antibiotics

- Receiving monoamine oxidase inhibitors (MAOI)s or drug which as significant MAOI activity (meperidine, linezolid, methylene blue) within 21 days of 1st dose of fludarabine

- Requiring potent CYP3A4 inducers or inhibitors

- Have ever had Serotonin Syndrome after receiving one or more serotonergic drugs

- Prior therapy with anti-CTLA-4 antibody, anti PD-1, or an experimental immune system-targeted therapy

- Use of any UGT1A9 inhibitor including: diclofenac, imipramine, ketoconazole, mefenamic acid, and probenecid from screening through follow-up period.

- Undergone an organ transplant(s) including allogeneic stem cell or bone marrow transplants.

- Unstable cardiovascular disease (eg, uncontrolled hypertension, peripheral vascular disease, congestive heart failure, cardiac arrhythmia, or acute coronary syndrome) within 6 months of starting study treatment.

- Any gastrointestinal condition causing malabsorption or obstruction (eg, celiac sprue, gastric bypass surgery, strictures, adhesions, history of small bowel resection, blind loop syndrome). Unable or unwilling to swallow tablets BID.

- Active autoimmune process (eg rheumatoid arthritis, moderate or severe psoriasis, multiple sclerosis, inflammatory bowel disease, etc.) or who have been receiving therapy for an autoimmune or inflammatory disease. Vitiligo, thyroiditis, or eczema is permitted if patient is otherwise eligible

- Known HIV-positivity

- History of hepatitis or positive serology as follows:

- Hepatitis B (HepB) screening testing required:

- HepB SAg (hepatitis B surface antigen);

- Anti-HepB SAg (antibody against hepatitis B surface antigen);

- Anti-Hepatitis B core IgG (antibody against hepatitis B core antigen).

- Hepatitis B core IgM antibody

- Hepatitis C screening testing required:

- HCV-antibody (antibody against hepatitis C virus);

- HCV-RNA (serum test for circulating virus, based on detecting RNA)

Study Design


Intervention

Drug:
Fludarabine
Fludarabine 25 mg/m^2 IV on days -6 through -2 from NK cell infusion
Cyclophosphamide
Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
Biological:
NK cells
CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
IL-2
IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
Drug:
INCB024360
INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)

Locations

Country Name City State
United States University of Minnesota Masonic Cancer Center Minneapolis Minnesota

Sponsors (2)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota Incyte Corporation

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose of INCB024360 To determine the maximum tolerated dose (MTD) of INCB024360 when administered with intraperitoneal haploidentical donor NK cells/IL-2 after a nonmyeloablative cyclophosphamide/fludarabine (Cy/Flu) preparative regimen in patients with recurrent ovarian, fallopian tube, and primary peritoneal cancer 90 days
Secondary Initial tumor response The proportion of patients with initial tumor response (CR or PR) 90 days
Secondary Duration of tumor response Duration of tumor response 1 year
Secondary Progression-free survival Average time to progression. 5 years
Secondary Overall survival Average length of survival after treatment 5 years
See also
  Status Clinical Trial Phase
Completed NCT02526017 - Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Phase 1
Withdrawn NCT05201001 - APX005M in Patients With Recurrent Ovarian Cancer Phase 2
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Not yet recruiting NCT06376253 - A Phase I Study of [177Lu]Lu-EVS459 in Patients With Ovarian and Lung Cancers Phase 1
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Recruiting NCT03412877 - Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer Phase 2
Active, not recruiting NCT03667716 - COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. Phase 1
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Recruiting NCT05156892 - Tamoxifen and SUBA-Itraconzole Combination Testing in Ovarian Cancer Phase 1
Suspended NCT02432378 - Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines Phase 1/Phase 2
Recruiting NCT04533763 - Living WELL: A Web-Based Program for Ovarian Cancer Survivors N/A
Active, not recruiting NCT03371693 - Cytoreductive Surgery(CRS) Plus Hyperthermic Intraperitoneal Chemotherapy(HIPEC) With Lobaplatin in Advanced and Recurrent Epithelial Ovarian Cancer Phase 3
Withdrawn NCT03032614 - Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients Phase 2
Completed NCT01936363 - Trial of Pimasertib With SAR245409 or Placebo in Ovarian Cancer Phase 2
Completed NCT02019524 - Phase Ib Trial of Two Folate Binding Protein Peptide Vaccines (E39 and J65) in Breast and Ovarian Cancer Patients Phase 1
Terminated NCT00788125 - Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors Phase 1/Phase 2
Active, not recruiting NCT05059522 - Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing Phase 3
Active, not recruiting NCT04383210 - Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors Phase 2
Terminated NCT04586335 - Study of CYH33 in Combination With Olaparib an Oral PARP Inhibitor in Patients With Advanced Solid Tumors. Phase 1
Terminated NCT03146663 - NUC-1031 in Patients With Platinum-Resistant Ovarian Cancer Phase 2